Related Experiment Video
Updated: Mar 3, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer
Raghav Sundar1,2, Maxime Chénard-Poirier1,3, Dearbhaile Catherine Collins1,3
1Royal Marsden Hospital, London, UK.
Abstract:
Over the past decade, major advances have been made in the management of advanced non-small cell lung cancer (NSCLC). There has been a particular focus on the identification and targeting of putative driver aberrations, which has propelled NSCLC to the forefront of precision medicine. Several novel molecularly targeted agents have now achieved regulatory approval, while many others are currently in late-phase clinical trial testing. These antitumor therapies have significantly impacted the clinical outcomes of advanced NSCLC and provided patients with much hope for the future. Despite this, multiple deficiencies still exist in our knowledge of this complex disease, and further research is urgently required to overcome these critical issues. This review traces the path undertaken by the different therapeutics assessed in NSCLC and the impact of precision medicine in this disease. We also discuss the areas of "imprecision" that still exist in NSCLC and the modern hypothesis-testing studies being conducted to address these key challenges.
Insights
Precision medicine has transformed advanced non-small cell lung cancer (NSCLC) care with targeted therapies. Further research is needed to address remaining challenges and improve outcomes for NSCLC patients.
Area of Science:
- Oncology
- Precision Medicine
- Molecular Targeted Therapy
Background:
- Significant progress in advanced non-small cell lung cancer (NSCLC) management over the last decade.
- Focus on identifying and targeting driver aberrations has advanced NSCLC in precision medicine.
- Novel molecularly targeted agents have gained approval, with more in clinical trials.
Purpose of the Study:
- To review the evolution of therapeutics for NSCLC.
- To assess the impact of precision medicine on NSCLC treatment.
- To identify current knowledge gaps and ongoing research addressing these challenges.
Main Methods:
- Literature review of therapeutic advancements in NSCLC.
- Analysis of the role and impact of precision medicine in NSCLC.
- Discussion of current hypothesis-testing studies addressing NSCLC treatment limitations.
Main Results:
- Targeted therapies have significantly improved clinical outcomes for advanced NSCLC.
- Several targeted agents are approved, and many are in late-stage trials.
- Despite advances, significant knowledge gaps and 'imprecision' remain in NSCLC management.
Conclusions:
- Precision medicine has brought hope and improved outcomes for advanced NSCLC patients.
- Continued research is essential to overcome existing challenges in NSCLC.
- Ongoing studies aim to address the 'imprecision' in current NSCLC treatment strategies.
More Related Videos
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019